Skip Navigation

European Heart Journal 2004 25(10):807-809; doi:10.1016/j.ehj.2004.04.010
Copyright © 2004 by the European Society of Cardiology.
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Büttner, H. J.
Right arrow Articles by Neumann, F.-J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Büttner, H. J.
Right arrow Articles by Neumann, F.-J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorial

Tirofiban for catheter intervention in acute myocardial infarction?

Heinz Joachim Büttner and Franz-Josef Neumann*

Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany

E-mail address: achim.buettner@herzzentrum.de

* Correspondence to: Prof. Dr. med. Franz-Josef Neumann, Herz-Zentrum Bad Krozingen, Südring 15, 79189 Bad Krozingen, Germany. Tel.: +49-7633-402-8201; fax: +49-7633-402-8204
E-mail address: franz-josef.neumann@herzzentrum.de

The first 10% of the full text of this article appears below.

This editorial refers to "Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial"1 by A.W.J. Van 't Hof et al. on page 837.

The primary goal of treatment in acute myocardial infarction is re-perfusion of ischaemic myocytes to salvage myocardium and thus improve the long-term clinical outcome. An indispensable pre-requisite for this goal is full patency (TIMI grade 3 flow) of the infarct-related artery. In 1993, the Zwolle group was among the first who published compelling data that this purpose is best served by percutaneous catheter intervention (PCI).1 Even in patients who need to be transported to the PCI center from another hospital, PCI is superior to fibrinolysis.2 A critical time limit for . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial
Arnoud W.J van't Hof, Nicolette Ernst, Menko-Jan de Boer, Rob de Winter, Eric Boersma, Ton Bunt, Sonia Petronio, A.T Marcel Gosselink, Walter Jap, Frans Hollak, Jan C.A Hoorntje, Harry Suryapranata, Jan-Henk E Dambrink, Felix Zijlstra, and on behalf of the On-TIME study group
EHJ 2004 25: 837-846. [Abstract] [FREE Full Text]  



This article has been cited by other articles:


Home page
 Eur Heart J SupplHome page
M. Ferenc and F.-J. Neumann
Efficacy of primary PCI: the microvessel perspective
Eur. Heart J. Suppl., October 1, 2005; 7(suppl_I): I4 - I9.
[Abstract] [Full Text] [PDF]